TDP6, a brain-derived neurotrophic factor-based trkB peptide mimetic, promotes oligodendrocyte myelination

Wong, Agnes W.; Giuffrida, Lauren; Wood, Rhiannon J.; Peckham, Haley; Gonsalvez, David G.; Murray, Simon S.; Hughes, Richard A.; Xiao, Junhua

doi:10.1016/j.mcn.2014.10.002

Cited by 36 publications

(39 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TDP6 and 29D7 have been shown to represent other promising BDNF mimetic molecules able to promote oligodendrocyte-mediated myelination in vitro (Wong et al 2014) and to enhance neuronal survival and neurotic outgrowth in vitro and in vivo as well as to provide long-lasting neuroprotection against neonatal hypoxic-ischemic brain injury (Kim et al 2014; Qian et al 2006). …”

Section: Future Directions: Targeting Growth Factor Signaling With Symentioning

confidence: 99%

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

et al. 2018

View full text Add to dashboard Cite

Depression is a major health problem with a high prevalence and a heavy socioeconomic burden in western societies. It is associated with atrophy and impaired functioning of cortico-limbic regions involved in mood and emotion regulation. It has been suggested that alterations in neurotrophins underlie impaired neuroplasticity, which may be causally related to the development and course of depression. Accordingly, mounting evidence suggests that antidepressant treatment may exert its beneficial effects by enhancing trophic signaling on neuronal and synaptic plasticity. However, current antidepressants still show a delayed onset of action, as well as lack of efficacy. Hence, a deeper understanding of the molecular and cellular mechanisms involved in the pathophysiology of depression, as well as in the action of antidepressants, might provide further insight to drive the development of novel fast-acting and more effective therapies. Here, we summarize the current literature on the involvement of neurotrophic factors in the pathophysiology and treatment of depression. Further, we advocate that future development of antidepressants should be based on the neurotrophin theory.

show abstract

Section: Future Directions: Targeting Growth Factor Signaling With Symentioning

confidence: 99%

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Does neuroligin-3 play a role in healthy neuron-OPC interactions? Does BDNF, crucial in myelin development (Xiao et al, 2010;Wong et al, 2013;Wong et al, 2014;Peckham et al, 2016) and remyelination (Vondran et al, 2010;VonDran et al, 2011;Fulmer et al, 2014), play a role in activity-regulated myelin plasticity? The parallel importance of the PI3K/AKT/mTOR pathway in both normal myelination (Flores et al, 2008;Tyler et al, 2009;Goebbels et al, 2010;Harrington et al, 2010;Guardiola-Diaz et al, 2012;Hu et al, 2013;Bercury et al, 2014;Lebrun-Julien et al, 2014;Goebbels et al, 2017) and in glioma suggests that further mechanistic parallels will come to light.…”

Section: Myelin Plasticity In Disease Cancermentioning

confidence: 99%

Bad wrap: Myelin and myelin plasticity in health and disease

Gibson

Geraghty

Monje

2017

Developmental Neurobiology

View full text Add to dashboard Cite

Human central nervous system myelin development extends well into the fourth decade of life, and this protracted period underscores the potential for experience to modulate myelination. The concept of myelin plasticity implies adaptability in myelin structure and function in response to experiences during development and beyond. Mounting evidence supports this concept of neuronal activity-regulated changes in myelin-forming cells, including oligodendrocyte precursor cell proliferation, oligodendrogenesis and modulation of myelin microstructure. In healthy individuals, myelin plasticity in associative white matter structures of the brain is implicated in learning and motor function in both rodents and humans. Activity-dependent changes in myelin-forming cells may influence the function of neural networks that depend on the convergence of numerous neural signals on both a temporal and spatial scale. However, dysregulation of myelin plasticity can disadvantageously alter myelin microstructure and result in aberrant circuit function or contribute to pathological cell proliferation. Emerging roles for myelin plasticity in normal neurological function and in disease are discussed. © 2017 Wiley Periodicals, Inc. Develop Neurobiol 78: 123-135, 2018.

show abstract

“…In these cases small molecules were developed that mimic a region of BDNF that binds to its receptor, trkB (Massa et al 2010, Wong et al 2014). While one of these mimetics promotes myelination of oligodendrocytes in culture (Wong et al 2014), another has been applied intranasally and restores motor learning deficits following traumatic brain injury (Massa et al 2010). Other approaches to enhancing BDNF's actions involve the development of chimeric peptides formed by the conjugation of BDNF to a monoclonal antibody to the blood brain barrier transferrin receptor.…”

Section: Approaches To the Therapeutic Application Of Growth Factorsmentioning

confidence: 99%

The role of growth factors as a therapeutic approach to demyelinating disease

Huang

Dreyfus

2016

Experimental Neurology

View full text Add to dashboard Cite

A variety of growth factors are being explored as therapeutic agents relevant to the axonal and oligodendroglial deficits that occur as a result of demyelinating lesions. This review focuses on five such proteins that are present in the lesion site and impact oligodendrocyte regeneration. It then presents approaches that are being exploited to manipulate the lesion environment affiliated with multiple neurodegenerative diseases and suggests that the utility of these approaches can extend to demyelination. Challenges are to further understand the roles of specific growth factors on a cellular and tissue level. Emerging technologies can then be employed to optimize the use of growth factors to ameliorate the deficits associated with demyelinating degenerative diseases.

show abstract

TDP6, a brain-derived neurotrophic factor-based trkB peptide mimetic, promotes oligodendrocyte myelination

Cited by 36 publications

References 36 publications

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

Bad wrap: Myelin and myelin plasticity in health and disease

The role of growth factors as a therapeutic approach to demyelinating disease

Contact Info

Product

Resources

About